Print Magazine
Brussels Morning Newspaper
Tuesday, October 3, 2023
No Result
View All Result
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Sustainable Perspective
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Sustainable Perspective
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
No Result
View All Result
Home Europe

Share increases seen amid vaccine news

Sophia Akram by Sophia Akram
10 November 2020
in Europe, Features
Share increases seen amid vaccine news
Share on FacebookShare on Twitter

London (Brussels Morning) The London FTSE 100 rose for the second day in a row as news of an effective COVID-19 vaccine continued to buoy optimism.

The index of blue-chip industries increased 1.2 percent Tuesday after a three-month high on Monday.

Other industries also showed gains, including energy, insurance and auto companies, as well as the FTSE 250.

“The market is currently split between investors who are optimistic about the vaccine and see a way out and those who still have doubts about it,” said Milan Cutkovic, an analyst at online trading company Axi.

He added that Brexit as well as the pandemic, was causing the UK market to underperform, putting pressure on the prime minister to keep the country from entering a deep recession.

Meanwhile, Pfizer, whose shares also increased as it announced its 90 percent effective trial results, and BioNTech, has said it will price the vaccine below “typical market rates” which will also vary according to country and region.

“We’ve tried to pursue a balanced approach that recognises that innovation requires capital and investment so we plan to price our vaccine well below typical market rates reflecting the situation that we’re in and with the goal to ensure broad-based access around the world”, said Ryan Richardson, head of strategy at the German biotech firm, speaking to the Financial Times.

The European Commission is due to discuss supply with the American and German partnership with a view to securing 300 million doses.

However, scientists have warned an 80 percent take up rate may be needed to protect communities from the virus adequately.

That objective could be risked if hesitancy around vaccines persist.

Thirty-six percent of people in Britain, for instance, say they are uncertain or unlikely to agree to a COVID-19 inoculation.

On this basis, it may take some time to sufficiently safeguard the population against the effects of the virus.

Tags: Coronavirus vaccineCovid 19
Follow Brussels Morning
Facebook Twitter Youtube Linkedin

About Us

Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.

More Info

  • About Us
  • Advertising
  • Cookie Policy
  • Contact Us
  • FAQ
  • Jobs

Categories

  • Belgium News
  • Brussels
  • Culture and Society
  • Economy
  • EU Institutions
  • Commission
  • Council
  • Parliament
  • Europe
  • Features
  • Health & Fitness
  • In Depth
  • Ambassador’s Corner
  • Europe With Transparency
  • Place de la Bourse
  • Southeast Europe
  • Sustainable Perspective
  • The American Angle
  • The Macro-Economist
  • Member States
  • Opinion
  • Our pick
  • Uncategorised
  • World
  • Diplomacy
  • Middle East Eye
  • US Elections
  • Join Our Newsletter

    Brussels Morning Newspaper – All Rights Reserved © 2020

    No Result
    View All Result
    • Home
    • About Us
    • Brussels Bubble
      • Parliament
      • Commission
      • Council
    • Wider Europe
      • Member States
    • World
    • Business & Society
    • Europe With Transparency
    • Culture & Society
    • Policy Talks
      • Place de la Bourse
      • The Macro-Economist
      • Sustainable Perspective
      • Ambassador’s Corner
      • The American Angle
      • Southeast Europe
    • Print Magazine

    Brussels Morning Newspaper - All Rights Reserved © 2020

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
    Cookie settingsACCEPT
    Privacy & Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
    Non-necessary
    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
    SAVE & ACCEPT